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Background 
Robotic-assisted surgery by the da Vinci Si appears to benefit rectal cancer surgery in selected patients, 
but still has some limitations, one of which is its high costs. Preliminary studies have indicated that the 
use of the new da Vinci Xi provides some added advantages, but their impact on cost is unknown. The 
aim of the present study is to compare surgical outcomes and costs of rectal cancer resection by the two 
platforms, in a single surgeon’s experience. 
 
Methods 
From April 2010 to April 2017, 90 robotic rectal resections were performed, with either the da Vinci Si 
(Si-RobTME) or the da Vinci Xi (Xi-RobTME). Based on CUSUM analysis, two comparable groups of 
40 consecutive Si-RobTME and 40 consecutive Xi-RobTME were obtained from the prospectively 
collected database and used for the present retrospective comparative study. Data costs were analysed 
based on the level of experience on the proficiency-gain curve (p-g-curve) by the surgeon with each 
platform. 
 
Results 
In both groups, two homogeneous phases of the p-g-curve were identified: Si1 and Xi1: cases 1–19, Si2 
and Xi2: cases 20–40. A significantly higher number of full RAS operations was achieved in the Xi-
RobTME group (p<0.001). A statistically significant reduction in operating time (OT) during Si2 and Xi2 
phase was observed (p<0.001), accompanied by reduced overall variable costs (OVC), personnel costs 
(PC) and consumable costs (CC) (p<0.001). All costs were lower in the Xi2 phase compared to Si2 phase: 
OT 265 vs. 290 min (p=0.052); OVC 7983 vs. 10231.9 (p=0.009); PC 1151.6 vs. 1260.2 (p=0.052), CC 
3464.4 vs. 3869.7 (p<0.001). 
 
Conclusions 
Our experience confirms a significant reduction of costs with increasing surgeon’s experience with both 
platforms. However, the economic gain was higher with the Xi with shorter OT, reduced PC and CC, in 
addition to a significantly larger number of cases performed by the fully robotic approach. 
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INTRODUCTION 
Robotic-assisted surgery (RAS) was introduced specifically to overcome the kinematic restrictions 
imposed on the operating surgeon by conventional laparoscopic surgery. RAS by the da Vinci Surgical 
system appears to benefit rectal cancer surgery, which in some early series included reduced conversion 
rates, reduced operative blood loss, greater residual mesorectal fascial integrity rate following pelvic 
dissection, shorter proficiency-gain curve (p-g-curve) and excellent functional results compared with the 
reported experience by the manual direct laparoscopic approach [1-8]. Nevertheless, even if not all these 
findings have been reported by the ROLARR trial [9] and by recent meta-analysis [10-12], potential 
advantages were confirmed in selected patients. However, the higher costs of RAS with the da Vinci 
remain a critical issue, and have prevented its widespread adoption. Additionally, there are other 
limitations to RAS by the da Vinci Si platform, including the limited flexibility for complete robotic multi-
quadrant operations, imposing technical difficulty in achieving complete mobilization of splenic flexure. 
Furthermore, if changes in the position of the robot and/or the patient are needed, the robotic system 
must be undocked to enable safe reposition of the entire platform and re-docking or, alternatively, the 
surgeon must use a hybrid laparoscopic/robotic approach. The introduction of the new da Vinci Xi 
platform and its subsequent added use of the da Vinci Table Motion (dVTM) has overcome these 
limitations. Preliminary studies have indicated that the use of the new da Vinci Xi with the dVTM is 
associated with a shorter operative time, reduced docking time, and higher full robotic resection rates 
compared to the previous da Vinci Si [13-21]. The possible impact of these advantages of da Vinci Xi on 
costs is unknown. Despite several published studies regarding clinical and surgical benefits of robot-
assisted colorectal surgery since the introduction of da Vinci Surgical System, to date few studies have 
reported a structured cost analysis, and none have analysed the possible differences in costs between da 
Vinci Si and new da Vinci Xi. The aim of this study is to compare surgical parameters and costs of robotic 
surgery for rectal cancer with the use of da Vinci Si and Xi surgical platforms. 
 
MATERIALS AND METHODS 
From April 2010 to April 2017, 90 robotic rectal resections were performed at the General Surgery Unit, 
University of Pisa, with the da Vinci Si (Si-RobTME) until December 2014, or with the da Vinci Xi (Xi-
RobTME) since January 2015. 
All the procedures were performed by a single surgeon previously experienced in rectal cancer surgery 
(>100 cases), with manual laparoscopic surgery (>100 cases), and who started his robotic experience with 
da Vinci Si in November 2009. 
For the present study, data on patient outcomes, surgical procedures, and postoperative course were 
retrieved from a prospectively collected institutional dedicated database. The preoperative work-up 
included colonoscopy with biopsy, abdominal and trans-rectal ultrasonography, chest radiography, 
abdomen and pelvic CT scan, and/or magnetic resonance imaging. Patients with clinical stage I cancer 
(T1-2, N0, M0) were referred for prompt surgical treatment. Patients with clinical stage II–III cancer 
with T3 and/or N-positive received neoadjuvant chemoradiation (continuous 5-FU infusion/ RT) 
followed by surgical resection within 8 weeks. T4 lesions were operated through an open approach and 
excluded from the study as were patients with clinical stage IV cancer (metastatic disease). Obesity (BMI 
>30 kg/m2) or previous abdominal or pelvic surgical procedures were not considered contraindication. 
An anterior resection of the rectum (ARR) was used for lesions with caudal margin located at least 3 cm 
above the dentate line. Intersphincteric resection (ISR) with direct manual colo-anal anastomosis was 
considered for lesions located between 3 and 0.5 cm above the dentate line, while lesions located less 
than 0.5 cm above the dentate line or with direct sphincter invasion, underwent an abdominoperineal 
resection (APR). A diverting ileostomy was performed in all ARR and ISR patients. The clinical variables 
included patient demographics, the American Society of Anaesthesiologists (ASA) scores, body mass 
index (BMI), neoadjuvant treatment and distance of the tumour from the anal verge were. The 
perioperative data were operating time (OT), docking time, the use of hybrid or full-robotic approach, 
and conversion to open or hand-assisted laparoscopic surgery (HALS). Postoperative data included 
length of stay and postoperative complication according to the Clavien–Dindo classification [22]. 
Cost data were obtained from the accounting department of the hospital and added to our institutional 
prospectively collected database. Costs were expressed in euros and referred to year 2016. Economic data 
were collected from the accounting department of the hospital. Because the study consisted of a 
comparison between two successive generations of the same robotic platform, we excluded from the 
analysis fixed costs (purchase and maintenance). In addition, stapler’s costs were excluded because since 
the introduction of the endo-wristed staplers, they are now available for both systems, they were not 
available at the time our Si interventions were performed, and so inclusion of these costs in the analysis 
would have introduced a bias. In fact, for valid representation of consumable costs in current practice, 
robotic EndoWrist staplers should have been considered for both Si and Xi interventions, and hence do 
not have any impact on relative costs between the two platforms. 
Overall variable costs (OVC) included items related to disposable instruments (consumable costs, CC), 
operating room personnel (personnel costs, PC), and length of stay (hospital stay costs, HC). Details of 
resources use and related costs are reported in Appendix (Table A1-A3). 
Considering OT as an indicator of the proficiency-gain process, the CUSUM method [23] was used to 
analyse the p-g-curve for the two da Vinci systems. This method comprises running the total of the 
differences between the individual data points and the mean of all data points. First, the cases were 
ordered chronologically, from the earliest to the last date of surgery. The value of CUSUM operative time 
(CUSUMOT) of the first case was then obtained as the difference between the OT for the first case and 
the mean OT for all the cases (mOT). The CUSUMOT of the second case was the CUSUMOT of the 
previous case added to the difference between the OT of the second case and mOT. The same procedure 
was repeated for each of the patients except the last one, which was marked as 0. 
Based on CUSUM analysis, two comparable groups of 40 consecutive Si-RobTME and 40 consecutive 
Xi-RobTME were identified. 
For the present study, clinical and costs data of these two groups were analysed and compared against 
the device specific robotic p-g-curve. To compare the variation of costs with the experience we also 
matched costs of each phase of the p-g-curve of the two groups. 
The study was approved by Institutional review board. All patients received an extensive explanation of 
the procedure and provided informed consent.  
 
Surgery 
Surgical technique 
For the Si-RobTME group, we used a single docking full robotic or hybrid technique, based on patient 
characteristics and intra-operative findings. Main criteria for the hybrid approach included difficulties in 
exposure of inferior mesenteric vein or splenic flexure; encroachment of the operative field by small 
bowel loops, visceral obesity and need of multiple changes of table position. 
The patients were placed in a modified lithotomy position with a 30° Trendelenburg and a tilt to the right 
side. In the full robotic technique, a 12mm optical trocar for the camera was inserted 3 cm to the right 
and lateral to the umbilicus. An 8-mm trocar for the robotic arm was placed under direct vision at the 
point of intersection between the mid-clavicular line and the line between the umbilicus and the anterior 
superior iliac spines on the right side. The other two robotic trocars were inserted in the epigastric region, 
one on the right either side of the falciform ligament. Another 12mm trocar in the right flank was inserted 
for use by the assistant surgeon. In the hybrid technique, the first part of the operation (inferior 
mesenteric vessel ligation, left colon and splenic flexure mobilization) was carried out laparoscopically. 
The trocar for the camera was in the same position as in the full robotic technique, the two operative 
trocars were epigastric (8mm) and suprapubic (12 mm), respectively; an 8mm robotic trocar was placed 
in the left flank. 
The choice for using a hybrid technique was made after placement of the optical trocar and the 
suprapubic trocar to expose and the evaluate quality of the operative field obtained with changes in the 
position of the operating table, being made as required. For the robotic step of the intervention (the 
TME), the cart was positioned to the patient’s left side, along an imaginary line between the anterior 
superior iliac spine and the umbilical scar, at a 60° angle. During this step, the surgeon inserted the 8mm 
trocar inside the 12mm one (trocar in trocar) and another 12mm trocar was placed in the right flank for 
the use by the assistant.  
In the Xi-RobTME group, patients were placed in a modified lithotomy position with a 30° 
Trendelenburg and a tilt to the right side. The first 8mm robotic trocar was placed in the umbilical region, 
along the right pararectal line. Four trocars were then inserted under vision in an oblique fashion 
following the classic universal port placement guidelines provided by Intuitive Surgical for ’left lower’ 
abdominal procedures that provides for positioning an 8mm port in the right iliac fossa, a 12mm 
assistant’s trocar in the right flank and two 8mm robotic ports in the periumbilical region and the left 
hypochondriac space, respectively. However, as previously reported [16-18], we prefer to locate all trocars 
by 2–5 cm to the right side, to enhance the workspace and facilitate the approach to the splenic flexure 
with the fourth arm. ‘Patient-left’ was the selected approach, and the surgical cart was driven to position 
the green laser crosshairs on the initial endoscope port. After docking, the scope was pointed at the 
inferior mesenteric pedicle of the sigmoid colon, and function ‘targeting’ was performed. The boom was 
then rotated in a clockwise direction to ensure the optimal configuration for dividing the inferior 
mesenteric pedicles and mobilizing the left colon up to the splenic flexure. In our initial experience, we 
performed a new targeting down to the pelvis with a consequent double docking. However, with 
increasing experience in performing TME we changed only the targeted anatomical site of the camera 
from the left side to the pelvis and changed the arm direction and the FLEX of each arm without the 
necessity to undock the robotic arms and a consequent second docking. The dVTM was used when 
necessary to obtain the optimal exposure of the operative field. 
The colon was exteriorized through a Pfannenstiel suprapubic mini-laparotomy and prepared for the 
anastomosis, which was performed with a double stapled end to end technique. In case of ISR, the 
specimen is exteriorized through the anus and a manual colo-anal anastomosis was performed. 
 
Statistical analysis 
Categorical variables were reported as number of cases and percentage, while continuous variables were 
expressed as mean ± (standard deviation) or median [25–75 percentile], depending on their distribution. 
The chi-square test and Fisher test were used to compare the distribution of categorical variables. For 
continuous variables, paired comparisons were made using an independent t test or Mann–Whitney test, 
while multiple comparisons were performed by means of an analysis of variance or Kruskal–Wallis test. 
The Bonferroni and Mann-Whitney test with Bonferroni correction were considered for post hoc test. 
Patient characteristics and perioperative data among Si-RobTME and Xi-RobTME subgroups identified 
through the CUSUM analysis were compared. Generalized linear models were used to estimate costs 
associated with the different surgical techniques and phases, adjusting for clinical characteristics and 
operative parameters. Variables with a p value <0.10 at univariate analysis were included in the 
multivariable analysis. A p value <0.05 was considered statistically significant. All analyses were per- 
formed using R v3.0.2 (R, Vienna, Austria), Stata version 12 (StataCorp, College Station, TX, USA) and 
SPSS (Statistical Production and Service Solution for Windows, SPSS Inc., Chicago, IL, USA). 
 
RESULTS 
The evaluation of the Si-RobTME and Xi-RobTME groups according to p-g-curve and based on the 
CUSUM analysis identified two homogeneous phases in both groups: Si1 and Xi1: cases 1–19, 
corresponding to the initial p-g-curve; Si2 and Xi2: cases 20–40 characterised by stabilization of OT 
(Figure 1). 
Demographic characteristics and preoperative condition of the two groups are summarized in Table 1. 
No significant differences in clinical features between the two groups were identified. Perioperative and 
pathological data are summarized in Table 2. There was no difference in the surgical procedures 
performed between the two groups. Mean overall operative time (OT) and mean docking time were 
significantly shorter in the Xi-RobTME: 283 ± 49 min vs. 311 ± 58 min in the Si-RobTME group 
(p=0.025), with a mean difference of -27.5 min (95% CI 3.6 - 51.4), and 16.8 ± 3.5 min in the Xi-RobTME 
group vs. 22.0 ± 2.5 min in the Si-RobTME group (p<0.01), with the mean difference of -5.3 min (95% 
CI 3.9 - 6.6), respectively. There were no conversions to conventional laparoscopy or HALS technique. 
The procedure was converted to a traditional open approach in one case in the Si-RobTME group for 
visceral obesity and in two cases in the Xi-RobTME group for the difficulty in identifying planes due to 
constant oozing from dissection planes because of a coagulopathy in a patient with liver cirrhosis, and 
for diffuses adhesions due to previous surgery and for anaesthesiologic problems in the second patient. 
No differences were reported between the two groups with respect to pathological findings. The mean 
distal resection margin was 2.3 ± 1.4 cm in the Si- RobTME group versus 2.4 ± 1.2 cm in the Xi-RobTME 
group (p=0.73). A mean of 17 ± 7 lymph nodes per patient were removed in the Si-RobTME group 
versus 19 ± 8.0 in the Xi-RobTME group (p=0.20). No patients had involvement of circumferential 
resection margins (≤1 mm) and the quality of the mesorectum, according to Quirke’s criteria [24] was 
‘complete’ in all cases. 
Post-operative data are summarized in Table 3. Median post-operative length of stay was significantly 
shorter in the Xi-RobTME group (7 days vs. 9.5 days, p<0.001). Post-operative complications occurred 
in 14 cases in the Si-RobTME group (grade I in 2, grade II in 10, and grade III in 2 on to the Clavien-
Dindo Classification) versus 10 cases in the Xi-RobTME group (grade I in 5, grade II in 4, and grade III 
in 1 according to the Clavien-Dindo Classification) (p=0.33). Four patients in the Si- RobTME group vs. 
one patient in the Xi-RobTME group (p=0.36) experienced transient small bowel obstruction, which 
resolved with insertion of a 24-F Foley catheter in the ileostomy. One patient in the Xi-RobTME group 
underwent laparoscopic exploration with closure of the ileostomy on 17th postoperative day for acute 
abdomen due to perforation of the afferent loop of the ileostomy (p=0.99). No in-hospital mortality was 
noted in the two groups. 
The comparison of patient characteristics and perioperative data by the CUSUM learning phases are 
summarized in Table 4. There were no differences in patient characteristics in the learning phases. The 
hybrid approach was used in a higher percentage of patients in the Si1 phase than Si2 phase (11 vs. 7 
cases) as distinct from no patients in the Xi1 and Xi2 phases (p<0.01). 
The comparison of costs incurred by the Si-RobTME and Xi-RobTME groups is summarized in Table 
5. Overall median variable costs associated with Xi-RobTME group were significant lower than with Si-
RobTME group: 7,687€ versus 10,242 €, respectively (p<0.001). Both costs related to the hospital stay, 
the cost of consumables and personnel were significantly lower in the Xi-RobTME (p<0.001, p<0.001 
and p=0.021, respectively). 
When comparing by robotic phases, OVC were lower in Xi1 and Xi2 compared to both Si1 (p<0.001 
and p=0.002) and Si2 (p<0.001 and p=0.009). A statistically significant change in OT by phase of robotic 
experience was detected (p <0.001). Mean OT was significantly lower in Si2 vs. Si1 (p=0.003), Xi2 vs. 
Xi1 (p=0.009) also Xi2 vs. Si1 (p<0.001) which reflected in PC. The reduction of OT with an increase 
of robotic experience is accompanied with reduction of PC (p<0.001), but statistically significant 
differences were present only when comparing the experienced vs. the initial phase in both Si (p=0.003) 
and Xi (p=0.009). A statistically significant reduction in CC by system and robotic phase was detected 
(p<0.001), and the CC of the Xi2 phase were significantly lower than both Si1 and Si2 phase (p<0.001). 
Moreover, HC showed a statistically significant difference by both system and robotic phase (p=0.001) 
with lower cost in the Xi1 phase compared to both Si1 and Si2 (p<0.001 for both). Only borderline 
significant difference was found in HC when comparing the Xi2 phase vs. the Si2 phase (3,302€ vs. 
4,717€, p=0.046).  
At multivariable analysis, when adjusting for potential confounding variables, OVC remained significantly 
lower in Xi2 as compared to both Si1 and Si2 (p=0.002 and p=0.030, respectively), CC of Xi2 was 
significantly lower than both phases of Si (p<0.001) while PC were lower in Xi2 compared to Si1 and 
Xi1 (p<0.001 and p=0.005 respectively) (Table 6). 
 
DISCUSSION 
The use of da Vinci robot has spread rapidly in colorectal cancer surgery even if its alleged reported 
advantages over the direct manual laparoscopic approach, including lower conversion rate, shorter p-g-
curve and improved functional outcomes (1, 3, 6-8, 18], have not been fully confirmed by the recently 
published randomized clinical trial, and meta-analyses [9-12]. The results of these studies indicate that 
selected patients, such as obese, men, those with cancer of the lower rectum, and patients operated after 
receiving preoperative chemoradiotherapy, are those for whom there is high-level evidence of superiority 
of RAS over direct manual laparoscopic surgery [25-30]. However, the downside of the RAS technique, 
which remains a critical issue preventing its widespread uptake, relates to its high capital, amortization, 
recurrent costs and longer operating time. In the da Vinci Si, the longer operative time is related to 
limitations intrinsic to this version, including its complicated setup, limited ability to reach all the 
abdominal quadrants without rearrangement of robotic arms, re-docking and/or repositioning of the 
surgical cart [18]. The increased costs associated with RAS result not only because of high purchase and 
maintenance costs of the robot, but also because of high costs of surgical consumables, and the longer 
operating room times confirmed by several publications [18, 31, 32]. However, one must stress that all 
the publications refer to experience based on use of the early versions of the da Vinci System including 
the penultimate one, the Si. The new da Vinci Xi with its innovations, has overcome some of the 
limitations of the preceding platforms. Indeed, preliminary studies have indicated that the use of the new 
da Vinci Xi by its technological improvements has the distinct potential to reduce significantly the 
operating time. Aside from having a shorter docking time, the Xi is more able to cope with multi-quadrant 
surgery, thereby increasing the full robotic execution of rectal cancer operations, when compared with 
the da Vinci Si [13, 15-18, 23]. Because these considerations, may translate to reduced costs, we 
considered the possibility that current reported literature may be exaggerating the increased costs 
associated with RAS by the da Vinci platform. This consideration has promoted the design and conduct 
of this cost analysis of a single surgeon’s first consecutive 40 robotic rectal resections with the da Vinci 
Si with the first consecutive 40 consecutive robotic rectal resections performed with the da Vinci Xi. In 
the process, the study also compared the phases of p-g-curve of the robotic experience by the two 
systems. The CUSUM method was used to analyse the p-g-curve based on the first 90 cases of robot-
assisted rectal cancer resection performed using both the da Vinci platforms. CUSUM p-g-curves are 
used as indicators to detect the acquisition of clinical proficiency in the execution of operations. This 
method of analysis allowed us to obtain two subgroups that reflect homogeneous phases: the first phase 
of learning and a second phase of stabilization of the times. Indeed, given that CUSUM is recognised as 
a method that provides quality control, it is well suited to analyse changes in parameters characterizing 
productive processes and hence identify “phases” within the process. For that reason, since our objective 
was to match phases of the process (not patients as it is common in clinical studies), this method was 
used to identify (and match) phases of the learning process. It has several advantages, including 
independence on sample size, effectiveness in detecting small changes, its ability to allow for a continuous 
analysis in time and rapid evaluation of data [23]. Many authors agree that the p-g-curve embraces 
different phases in which surgeons first gain robotic skills and then, with increasing familiarity with the 
new technique and new technology, the surgeon is able to decrease in OT and hospital costs over time 
[23, 33-35]. In changing from da Vinci Si to da Vinci Xi, the surgeon must deal with the novel aspects of 
the new platform such as different trocar placements, robotic cart position, new functions (pointing, 
targeting, camera hopping, etc.), new docking system and robotic arms regulation [18]; even if the surgeon 
is already expert in both laparoscopic and robotic laparoscopic rectal resections. We have reported 
previously that after the first two cases of rectal resection performed with the da Vinci Xi, in which the 
‘classic’ Universal Port Placement Guidelines provided by Intuitive Surgical for ‘left lower’ abdominal 
procedures was used, a modification of the trocar placement was used [16], which facilitates the approach 
to the transverse colon and splenic flexure by increasing the manipulation space, without causing 
difficulties during the pelvic phase, only possible by the intrinsic flexibility of the da Vinci Xi [18]. With 
further experience, we changed our surgical technique of robotic rectal resection with da Vinci Xi further 
by replacing the double targeting technique during the first phase, consisting of initial targeting the 
mesenteric vein isolation and splenic flexure mobilization, followed by the second targeting the pelvis, to 
a single targeting technique modifying only the FLEX of the robotic arm for the two phases of the 
operation with a further reduction of the operating time. All these modifications are features of a 
proficiency-gain phase for the first Xi cases. 
Our costs analysis revealed a significant decrease of OVC with surgeon’s experience. The impact on 
reduction of costs with surgeon’s experience is in accordance with data reported in our previous costs 
analysis comparing laparoscopic rectal resection with robotic rectal resection performed with the da Vinci 
Si [23]. Although the documented cost reduction is likely to be multifactorial, the optimization of 
instrument use and reduction of OT are two major contributors [23]. A further decrease of costs is clearly 
related to the shift from the Si to the Xi technology and is characterised by the significant reduction in 
OT, PC and CC associated with use of the new da Vinci Xi. However, the significant reduction of HS 
with the da Vinci Xi vs. Si-RobTME must be treated with caution, as the data on HS is subject to bias. 
Thus, it can be explained by the difference in post-operative complications in the two groups or could 
be secondary to an enhanced recovery protocol in Xi-RobTME group. Additionally, because the Si-
RobTME group included patients treated during our early experience with the robotic surgery, a more 
cautious policy may have been used for discharging patients from hospital [36]. 
In contrast, we believe that the reduction of OT and the improved ability to perform the procedure by a 
fully robotic approach offered by the da Vinci Xi are the two main factors influencing the reduction of 
costs. Indeed, the technological improvements offered by the da Vinci Xi, i.e., increased flexibility and 
range of motion of the cart and arms, as well as the ability to obtain the excellent exposure of the operative 
field without repositioning the patient have contributed to shorter operative and console times and the 
increased rate of fully robotic resections, well documented in the literature [15-17, 19, 20]. The reduction 
of the OT has influenced in turn reduction in PC because of a lower Operative Room (OR) hours. Our 
observation is in line with those recently report by Patel et al. in urology, that revealed in a comparative 
study with the da Vinci Si, that the da Vinci Xi robotic nephroureterectomy reduced overall HC due to 
the reduction of anaesthesia and OR cost [37]. The significant reduction of the CC, was mainly due to 
the higher number of full robotic operations achieved with the da Vinci Xi, because it avoids the use of 
laparoscopic instruments and devices for the laparoscopic phase used in the hybrid technique. 
The main limitations of the present study are its retrospective nature and the small sample size, which 
preclude definitive conclusions. In addition, as the study is based on experience of a single surgeon, its 
more general application to robotic-assisted rectal cancer surgery is limited without further collaborative 
studies. A further limitation imposed by the study design was the exclusion of capital costs and 
amortisation from the analysis. Hence, we acknowledge that their inclusion would be necessary for a 
complete assessment of overall costs. 
However, the present study, the first to compare costs incurred using the new da Vinci Xi with its 
predecessor has produced cost differences, some of which are significant, but obviously further larger 
structured cost analysis studies are needed to confirm the cost minimization by the da Vinci Xi. 
Perhaps, the most important take home message from the present study is to highlight that the current 
economic evaluation on robotic assisted surgery that have provided unfavorable cost comparisons 
between robotic assisted surgery compared to manual direct laparoscopy surgery, have all been based on 
studies performed with the da Vinci Si, and further compounded by comparing expert laparoscopic with 
novice robotic surgeons. The use of the new robot Xi, with case series being performed by expert robotic 
surgeons represents a totally different proposition, requiring careful objective re-evaluation of relative 
costs between the two surgical approaches. 
 
CONCLUSIONS 
In conclusion, the similar p-g-curve for both groups were likely due to a ‘proficiency-gain effect’ related 
mainly to the use of a new robotic technology, and not to the surgical operation itself. In taking up the 
new technology, the surgeon initially becomes familiar with new trocar placements, robotic cart position, 
new functions (pointing, targeting, camera hopping, etc.), new docking system and robotic arms 
regulation. Beyond this initial familiarization stage, the study has documented a significant decrease of 
costs with increasing surgeon’s experience, and change from the Si to the Xi da Vinci, which is 
characterised by shorter OT, PC, and reduction in the CC, together with enabling a higher number of 
full robotic operations than previously possible with the da Vinci Si. However, the important limitation 
of robotic TME rectal resection for cancer, and of robotic surgery in general that persists relates to the 
high fixed costs. Efforts to reduce these are essential for both long-term financial sustainability of robotic 
surgery and increased uptake of RAS needed to improve the outcome of patients undergoing curative 
surgical excision of solid cancers resulting from technical advantages offered by the robotic platforms.  
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Figure Legend 
 
Figure 1 – RobTME operative time (OT): CUSUM chart for OT (Panel a) for the Si-RobTME group 
(left) and the Xi-RobTME group (right); Plot of OT against case number (Panel b) for the Si-RobTME 
group (left) and the Xi-RobTME group (right). 
